Shandong New Time Pharmaceutical
Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent.
Overview
Shandong New Time Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2, 2/3, 3), testing F182112, F182112 single-agent, Pomalidomide in relapsed or refractory multiple myeloma, relapsed or refractory multiple myeloma (rrmm), cancer of unknown primary site. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Similar pages
not linked directly; found by shared links- TreatmentF182112
Shares A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma, A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.
- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Konruns Pharmaceutical
Shares the tags china, registry-only.
- CompanyBeijing Mabworks Biotech
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.